Last reviewed · How we verify
dihydroartemisinin-piperaquine plus azithromycin — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
dihydroartemisinin-piperaquine plus azithromycin (dihydroartemisinin-piperaquine plus azithromycin) — Liverpool School of Tropical Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| dihydroartemisinin-piperaquine plus azithromycin TARGET | dihydroartemisinin-piperaquine plus azithromycin | Liverpool School of Tropical Medicine | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- dihydroartemisinin-piperaquine plus azithromycin CI watch — RSS
- dihydroartemisinin-piperaquine plus azithromycin CI watch — Atom
- dihydroartemisinin-piperaquine plus azithromycin CI watch — JSON
- dihydroartemisinin-piperaquine plus azithromycin alone — RSS
Cite this brief
Drug Landscape (2026). dihydroartemisinin-piperaquine plus azithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/dihydroartemisinin-piperaquine-plus-azithromycin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab